Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of fluorometholone and sodium hyaluronate is used primarily for treating dry eye syndrome, particularly after cataract surgery and for patients with xerophthalmia (dry eyes). This combination provides both anti-inflammatory effects from the fluorometholone component and lubricating/moisturizing benefits from the sodium hyaluronate component. Fluorometholone is a corticosteroid eye medication that reduces inflammation in the eye[1][2]. It works by calming the immune system to reduce swelling and inflammation[2]. Sodium hyaluronate is a lubricant that moistens the eyes and provides temporary relief from burning and discomfort[7]. Studies have shown that the combination of these two medications, particularly in preservative-free formulations, can significantly improve clinical symptoms and tear film stability in patients with dry eye syndrome[4][5]. The combination has been found to have anti-inflammatory and antioxidant effects in tears of patients with dry eye syndrome[3][5]. ## Mechanism of Action Fluorometholone works as a steroid eye medicine that calms the immune system to reduce swelling and inflammation in the eye[2]. It helps treat eye conditions caused by inflammation, including certain eye infections, injuries, keratitis, iritis, and symptoms of conjunctivitis caused by seasonal allergies[2]. Sodium hyaluronate functions as a lubricant that moistens and lubricates the surface of the eye, making it feel more comfortable[10]. It stabilizes the natural tear film and maintains necessary lubrication to prevent dryness and irritation[7]. When used together, these medications work synergistically - fluorometholone reduces inflammation while sodium hyaluronate provides lubrication and moisture to the eye surface. ## Clinical Evidence Research has demonstrated that this combination can: - Significantly improve clinical symptoms and tear film stability in patients with xerophthalmia[4] - Regulate ocular surface inflammatory factors[4] - Improve symptoms and signs of dry eye syndrome after cataract surgery[3][5] - Decrease oxidative and inflammatory damage to the ocular surface[5] Preservative-free formulations of this combination have shown superior results compared to preserved formulations, with better outcomes in ocular surface disease index scores, tear-film breakup time, Schirmer scores, and other clinical measures[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorometholone + sodium hyaluronate.